$26.54
0.93% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US45166A1025
Symbol
IDYA
Sector
Industry

IDEAYA Biosciences Inc Stock price

$26.54
-2.76 9.42% 1M
-11.17 29.62% 6M
-9.04 25.41% YTD
-5.13 16.20% 1Y
+2.54 10.58% 3Y
+19.10 256.72% 5Y
+15.35 137.18% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.25 0.93%
ISIN
US45166A1025
Symbol
IDYA
Sector
Industry

Key metrics

Market capitalization $2.29b
Enterprise Value $1.39b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 355.27
P/S ratio (TTM) P/S ratio 585.18
P/B ratio (TTM) P/B ratio 1.94
Revenue growth (TTM) Revenue growth -83.30%
Revenue (TTM) Revenue $3.92m
EBIT (operating result TTM) EBIT $-224.75m
Free Cash Flow (TTM) Free Cash Flow $-153.27m
Cash position $920.03m
EPS (TTM) EPS $-2.33
P/E forward negative
P/S forward 392.38
EV/Sales forward 238.22
Short interest 12.01%
Show more

Is IDEAYA Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

IDEAYA Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a IDEAYA Biosciences Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a IDEAYA Biosciences Inc forecast:

Buy
93%
Hold
7%

Financial data from IDEAYA Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3.92 3.92
83% 83%
100%
- Direct Costs 4.22 4.22
21% 21%
108%
-0.29 -0.29
101% 101%
-7%
- Selling and Administrative Expenses 27 27
35% 35%
689%
- Research and Development Expense 193 193
67% 67%
4,930%
-221 -221
91% 91%
-5,626%
- Depreciation and Amortization 4.22 4.22
21% 21%
108%
EBIT (Operating Income) EBIT -225 -225
89% 89%
-5,733%
Net Profit -178 -178
73% 73%
-4,544%

In millions USD.

Don't miss a Thing! We will send you all news about IDEAYA Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IDEAYA Biosciences Inc Stock News

Neutral
PRNewsWire
8 days ago
Brings over 20-year global commercialization experience in oncology with leading biopharmaceutical companies Gilead Sciences and Bristol Myers Squibb, including leadership of multiple commercial launches for products including Trodelvy® and Opdivo® SOUTH SAN FRANCISCO, Calif. , Nov. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed ...
Neutral
PRNewsWire
14 days ago
SOUTH SAN FRANCISCO, Calif. , Nov. 12, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the Jefferies London Healthcare Conference and its plans to host an Investor R&D Day in December 2024.
Neutral
Business Wire
15 days ago
BEIJING & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ADC--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, has exerci...
More IDEAYA Biosciences Inc News

Company Profile

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Yujiro Hata
Employees 124
Founded 2015
Website www.ideayabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today